Apotheken | Arzt | Interaktionen | Medikamente | MiGeL | Services | Spital | Zulassungsi.
L03AB07 - Interferon Beta-1aATC-DDD Version 2016. Source: WHO
L - Antineoplastic and Immunomodulating Agents

This group comprises preparations used in the treatment of malignant neoplastic diseases, and immunomodulating agents.
Corticosteroids for systemic use, see H02.

L03 - Immunostimulants

Immunosuppressants, see L04A.

L03A - Immunostimulants

Levamisole, which also affects the immune response, is classified in P02CE.

L03AB - Interferons

Peginterferon alfa-2b in combination with ribavirin and peginterferon alfa-2a in combination with ribavirin are classified in L03AB60 and L03AB61, respectively.

The DDD for interferon alfa is based on the treatment of chronic active hepatitis B, whilst the DDD for interferon beta is based on the treatment of multiple sclerosis.
The DDDs of interferon beta-1a is based on i.m. administration.

L03AB07 - Interferon Beta-1a
4.3 mcgP 
2020 ©ywesee GmbH
Einstellungen | Hilfe | FAQ | Anmeldung | Kontakt | Home